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Fructose consumption can lead to marked increases in plasma triglycerides in both 
humans and laboratory animals.  We have observed that overnight access to a 16% 
fructose solution can promote hypertriglyceridemia in rats. Several investigators have 
suggested that APOC 3 may be implicated in promoting fructose-induced 
hypertriglyceridemia.  Wehave examined the role of APOC 3 in liver and blood taken 
from rats that had been given access to a fructose solution overnight as a supplement 
to standard laboratory chow.  Hepatic APOC3 mRNA expression from fructose alone 
resulted in a 14 % reduction compared to control. Interestingly, hepatic APOC3 
expression was increased by about 250% in sucrose, high fructose corn syrup and 
glucose groups. The serum protein levels of APOC3 did not differ across groups. 
Contrary to our hypothesis, these results indicate that glucose containing sugars 
increased hepatic APOC3 mRNA expression but no sugar was capable of increasing 
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Fructose is a sugar that has unique attributes that facilitate its conversion into 
body fat. We and others have reported that fructose consumption can quickly put into 




intake and abdominal fat stores.  The present review focuses on one of the most 
robust effects of fructose consumption – that of a rapid and significant rise in 
circulating triglycerides. We have divided this review into three sections.  In the first, 
we summarize some of the ways that fructose affects intake and metabolism.  We 
then contrast the metabolic pathways used by fructose with those used by glucose.  
The comparison makes it clear how fructose has a unique advantage in promoting 
hypertriglyceridemia.  We finish this review by organizing the existing literature so 
that the reader can quickly become familiar with specific topics of how fructose can 





  Nikkila and Ojala1  were among the first to report that fructose consumption 
leads to a dramatic increase in circulating triglycerides.  Since that time fructose-
induced hypertriglyceridemia (FIH) has been reported by dozens of investigators 2-4, 
many of whom have proposed mechanisms to explain how fructose uniquely and 
quickly is converted from sugar to circulating fat.  This review attempts to summarize 
the major factors involved in FIH.  It is by no means comprehensive, and we 
apologize if we have inadvertently omitted someone’s contribution to the literature. 
On the other hand, we hope that this introduction to the phenomenon contributes to a 
deeper understanding of how fructose can be added to the long list of factors 
promoting obesity, particularly abdominal obesity. 
The obesity epidemic that we are experiencing in the US is a national concern 
that affects all Americans.  It does not discriminate among age, race, class, or gender. 
In 1985 the rate of obesity across our country was under 14%; but by 2010 the rate 
exceeded 30%5.  Furthermore, obesity is quickly becoming a leading cause of major 
health problems and death6. The research community, along with policy makers and 
health care officials are grappling to find the causes of this relatively sudden increase 
in American’s girth. Several researchers have targeted high-fructose corn syrup as a 
potential accomplice supporting the obesity epidemic7-10.  They and their supporters 
have pointed out that fructose has become more prevalent in our diets over the past 
century. In 1900 the average fructose intake was 15g/day. Fructose was consumed 
mainly through eating fruits and vegetables, which have the added benefit of fiber11. 




consumed in highly processed forms11. One particularly attractive hypothesis linking 
obesity and fructose consumption is that increased fructose intake can disrupt normal 
hepatic metabolism leading to increased hepatic lipogenesis12.  The purpose of this 
review is to summarize the evidence supporting this hypothesis all the while focusing 
on one manifestation of this disruption, that of fructose-induced hypertriglyceridemia. 
Fructose and Appetite 
It is currently believed that normal hunger and satiety signals operate to alert 
the body when to initiate or end eating. One of these protein signals, leptin, decreases 
food intake when in excess and is therefore said to have anorexigenic effects12,13. 
Leptin is produced within adipose cells in relation to the amount of adipose in the 
body and travels to the arcuate nucleus. When excess adipose tissue exists, there is 
excess leptin produced signaling the body to stop eating. Another signal, ghrelin, is 
produced in the absence of food in the stomach and stimulates food intake14,15. 
Ghrelin is said to have orexigenic effects and travels through the blood system to the 
hypothalamus to signal hunger15. Recently, we have reported that overnight access to 
sucrose or fructose solutions can dramatically increase liver 11 β hydroxysteroid 
dehydrogenase – 1, an enzyme that is linked to omental obesity16,17.  Further, we have 
demonstrated that both fructose and sucrose can have significant effects on 
hypothalamic leptin, ghrelin and several other factors that help to control appetite18,19.  
We believe that dietary obesity arises when normal hunger and satiety signals are 
disrupted causing food intake disregulation in the form of overeating. While fructose 
has become a target of many research topics surrounding obesity, it is important to 




and one of fructose. Not surprisingly, sucrose and fructose have both been shown to 
have similar effects on weight gain. 
Fructose can increase the palatability of some foods and as a result can cause 
normal signals for fullness to be ignored, thereby allowing for increased intake and 
subsequent weight gain20,21. Others have confirmed this effect with other sugars, 
showing sugary foods motivate intake despite satiety22. Rats fed high fructose diets 
had increased body adiposity after 3-6 weeks23-25. Furthermore, rats continually fed 
fructose develop leptin resistance, which in turn accelerates high-fat induced 
obesity26.  Additionally, diet-induced obesity causes leptin resistance in both leptin 
transport across the blood-brain barrier as well as central leptin signaling in mice27. 
Thus the long-term consequences of fructose consumption and weight gain may 
override normal satiety signals.  
Fructose and Reward 
In addition to the effect of fructose on satiety signals, sucrose can induce 
addiction-like behaviors such as bingeing and dependence28-30. Hoebel and his 
associates have shown that underweight rats release more dopamine in the nucleus 
accumbens during a sucrose binge, indicating a potential mechanism for how sucrose 
may induce addiction-like behaviors31. Additionally, intermittent sucrose bingeing 
decreased D2 receptors and µ-opioid receptors in rats, which is an effect similar to 
that seen with morphine, indicating a role for sucrose in reward via its dopamine 
pathway32. These data make it clear that sugar (either sucrose or fructose) can have a 
major impact on reward and possibly addiction, as both phenomena are mediated by 




foods override satiety and result in overeating through mechanisms other than directly 
affecting satiety signals of the hypothalamus. 
 
 
Fructose and Liver 
Sugar also has effects on peripheral metabolic mechanisms that influence 
intake.  For example, fructose may increase lipogenesis in the liver beginning at the 
molecular level. Miyazaki33 reported that sterol regulatory element-binding protein-1 
(SREBP-1), an integral part of hepatic lipogenesis, was increased in the livers of rats 
receiving high-fructose diets.  This enzyme is a critical factor that transforms excess 
energy into triglycerides. Thus, when in excess SREBP-1 will increase triglyceride 
formation. Additionally, elevated levels of glucocorticoids have been linked to 
visceral obesity and metabolic complications34. In a recent study 11-β hydroxysteroid 
dehydrogenase -1 (11-βHSD-1, a regulator of intracellular glucocorticoids) was 
increased in the livers of rats after 24-hours of fructose access17. Additionally, sucrose 
increases 11β-HSD1 in adipose tissue, which is a characteristic of human and animal 
models of obesity15. In a study that assessed the effect of fructose and glucose in 
humans, overweight and obese subjects consuming 25% of their energy (10 weeks) as 
either glucose or fructose sweetened beverages gained weight regardless of the type 
of sugar used34. Interestingly, in subjects consuming fructose the visceral adipose 
volume was significantly higher than both control and glucose groups34. Rats fed high 
fructose diets (6 weeks) displayed hypertriglyceridemia, hyperinsulinemia, and 




help regulate carbohydrate and lipid metabolism, which decrease and increase 
respectively in response to chronic fructose consumption35. Taken together, these 
results indicate a potential connection between liver metabolism dysfunction, 
fructose, and increased visceral obesity.  
Based upon all of the above, it seems to be clear that sugars, and particularly 
fructose, have the potential of being major contributors in supporting at least part of 
the obesity epidemic.  However, not all authorities agree that sugar consumption is 
solely responsible for it. For example, the American Heart Association concluded that 
CVD and sugar consumption is not linked and that the effect on triglycerides seen 
with a high-sugar, high-carb diet can be reduced through exercise.  Fried has 
proposed that long term, randomized clinical studies are needed to assess if there is a 
threshold at which fructose and sucrose content in diets can cause abnormalities in 
triacylglycerol metabolism.   
The work summarized above reviews how sugars enter our diets and our 
bodies, and how they bypass some of the controls of intake and metabolism.  The 
following section of this review attempts to outline how fructose is metabolized, and 
how it uniquely contributes to adiposity via hypertriglyceridemia. 
II. Fructose metabolism – An Overview 
Before attempting to explain how fructose causes hypertriglyceridemia, a 
short review of how it is absorbed and metabolized may be of help. 
Absorption  
 Glucose is readily absorbed through the intestinal lumen via a diffusive 




(SGLT) in humans36-39. GLUT-2 is found on the basolateral membrane of epithelial 
cells to transport glucose into circulation37. GLUT-2 exhibits a low affinity for 
fructose and is responsible for a fraction of fructose absorption37. In contrast, many 
investigators reported that intestinal fructose absorption is incomplete in humans40-42.  
Fructose is predominantly taken into the intestinal epithelial cells from the intestinal 
lumen passively via GLUT-5 protein transporter in humans42. GLUT-5 is also 
expressed on the basolateral side of the intestinal epithelial cells to allow for fructose 
to exit the epithelial cell and enter into circulation43. Some evidence suggests that 
fructose can exit epithelial cells via GLUT-2 as well as GLUT-5 44.  
The liver can extract 40-70% of dietary fructose in both rats and humans 45-48. 
The high efficiency of fructose extraction by the liver is due to the fact that the liver 
is the main source of GLUT-542. Anatomically, the liver is the first organ to receive 
absorbed nutrients via the portal vein and, in that way contributes to its role in 
fructose extraction. By contrast, the liver accounts for a smaller percentage of glucose 
extraction for glycogen restoration49.  
Fructose Metabolism 
Fructose metabolism is best understood by considering three enzymes: 
fructokinase, aldolase B, and triokinase.  All three of these are only found in the liver 
and kidneys of rats and humans. In the liver, fructose is rapidly converted to fructose-
1-phosphate via fructokinase. Fructose -1-phosphate is then converted into the trioses 
dihydroxyacetone-phosphate and glyceraldehyde via the enzyme aldolase B.  
Aldolase B also functions in the liver for normal glycolysis (glucose metabolism). 




until this point in fructose metabolism, there have been no rate limiting steps and as a 
result there is an increased amount of substrate leading to metabolic pathways from 
triose phosphate (ie, glycolysis. glycogenesis, glyconeogenesis, and lipogenesis, 
fatty-acid esterification). Glyceraldehyde-3-phosphate is next metabolized to pyruvate 
via the rate-limiting enzyme pyruvate kinase. Fructose enhances activation of 
pyruvate kinase and thus leads to an increased flux of pyruvate into the Kreb’s cycle. 
It should be noted that fructose metabolism does not promote an insulin response.   








Glucose typically enters liver cells and is phosphorylated via glucokinase to 
form glucose-6-phosphate. Glucose-6-phosphate has two fates: conversion to 
fructose-6-phosphate via phosphoglucose isomerase,  or storage in the form of 
glycogen. Fructose-6-phosphate is further phosphorylated by phosphofructokinase to 
produce fructose-1, 6-bisphosphate. Phosphofructokinase is the main rate-limiting 
step in glycolysis. Aldolase, as seen in fructose metabolism, next converts fructose-1, 
6-bisphosphate into dihydroxyacetone-phosphate and glyceraldehyde-3-phosphate. 
Dihydroxyacetone-phosphate is at the crossroads between glucose and fructose 
metabolism51,12. The metabolic fate of glucose relies heavily on the body’s energy 
needs at the time. The integrated pathways of glucose metabolism include 
glycogenesis, glycogenolysis, glycolysis, pentose phosphate pathway, lipogenesis and 







Theories on Fructose-Induced Hypertriglyceridemia 
 A diet high in fructose can produce adverse metabolic changes such as 
increased plasma triglycerides (TG), hepatic insulin resistance, and hepatic 
steatosis52. These changes usually occur in people consuming large amounts of 
fructose and under hypercaloric conditions52. Tappy has suggested that sugar calories 
should be limited to 140kcal/day for men and 100kcal/day for women52. Fructose can 
alter normal lipid metabolism in the liver by generating unregulated surges of 
pyruvate. Pyruvate enters the mitochondria via pyruvate dehydrogenase and forms 




citric acid cycle, lipogenesis, and the formation of ketone bodies. In the lipogenic 
pathways Acetyl-CoA is shuttled across the mitochondrial membrane as citrate and is 
restored back to Acetyl-CoA in the mitochondrial cytosol via ATP-citrate lyase. Here 
Acetyl-CoA provides substrate to the production of long-chain fatty acids. Fatty acid 
synthase is a multi-enzyme complex that helps facilitate the conversion of Acetyl-
CoA to long-chain fatty acids. Rats fed 63% fructose for 24-48 hours and then fasted 
developed liver steatosis because fructose is highly lipogenic53,54. 
 Most of what has been presented above focuses on the potential effects of 
fructose consumption.  We should point out that not only can these shifts in 
metabolism take place, but there is growing evidence that they are taking place in the 
population.  For example, the amount of added sugars in the average American diet is 
currently 477kcal/day10.  This is in contrast to the recommendation from the WHO 
that only 10% energy of total daily intake come from added sugars55. Stanhope and 
her associates have shown that leptin production drops by 20-30% when subjects 
consumed fructose-sweetened beverages (30% caloric intake) compared to glucose-
sweetened beverages56,57. They hypothesize that the leptin reduction observed during 
prolonged consumption of diets high in fructose may lead to increased energy intake 
and/or decreased energy expenditure and weight gain. In fact, in subjects consuming 
fructose there is a decrease in energy expenditure and fat oxidation when compared to 
subjects consuming glucose. In rhesus monkeys, the consumption of fructose over a 3 
and 6 month period resulted in significant weight gain and decreased energy 
expenditure10. In a steady state fructose feeding study, postprandial levels of VLDL-




contributes to this rise10. Rebollo55 has reported that sucrose sweetened beverages 
significantly increases TG deposition in the liver, skeletal muscle, and visceral 
adipose tissue. Additionally, fructose consumption can increase TG over a 24-hour 
period, as well as apoB concentration56.  In a study comparing the effects of 
consuming glucose, fructose or HFCS (25% energy) TG increased during HFCS and 
fructose consumption over a 24-hour period57. Fasting LDL and apoB concentrations 
were also increased as a result of fructose and HFCS consumption57. In an earlier 
separate study assessing the effect of fructose and glucose in humans, Stanhope34  
reported that overweight and obese subjects consuming 25% of their energy over 10 
weeks as either glucose or fructose sweetened beverages all gained weight regardless 
of the type of sugar used. Interestingly, in subjects consuming fructose the visceral 
adipose volume was significantly higher than in both control and glucose groups. 
 
Additional Factors Contributing to Fructose Induced Hypertriglyceridemia 
 Recently, it has been discovered that hepatic lipogenesis is regulated by 
several transcription factors, most notably the sterol regulatory element-binding 
protein (SREBP-1c) and the carbohydrate responsive element binding protein 
(CHREBP)58,59. SREBP-1c can induce expression of the fatty acid synthase complex, 
which leads to an increase in triglyceride production and secretion60.  Fructose 
increases hepatic expression of the SREBP-1 & CHREBP families and thus the 
lipogenic enzymes responsible for triglyceride synthesis59,61.  
 Additional discoveries of peroxisome proliferator-activated receptors alpha 




The peroxisome proliferator-activated receptor gamma co-activator-1 (PGC-1β) 
elicits how SREBP-1c can regulate and influence lipogenesis63. PGC-1β is a direct 
co-activator of the transcription factor for SREBP-1c. Interestingly, Nagai showed 
that PGC-1β knockout studies protected rats from fructose-induced hyperlipidemia61.  
Peroxisome proliferator-activated receptor alpha (PPAR-α) is a liver 
transcription factor that enhances fatty acid β-oxidation. Fructose directly suppresses 
PPAR-α, which leads to less fatty acid oxidation and in that way promotes 
hypertriglyceridemia. In rats fed 10% fructose solutions PPAR-α was reduced while 
these changes were not observed in glucose fed rats64. Additionally, fructose reduced 
levels of hepatic fatty oxidation and increased levels of the pro-inflammatory 
transcription factor, nuclear factor Κ-β (NFK-β)64. Many compounds, such as fibrates 
and some fatty acids successfully enhance PPAR-α activity and remedy fructose-
induced hypertriglyceridemia61.    
No list of factors promoting fructose-induced hypertriglyceridemia would be 
complete without including the forkhead transcription factor (FOXO1), which is 
involved in carbohydrate and lipid metabolism. FOXO1 is required for the activation 
of gluconeogenic gene expression in hepatic cells65. Fructose can stimulate FOXO1 
expression, which favors a gluconeogenic state66. Additionally, it has been suggested 
that FOXO1 increases hepatic expression of a potent lipoprotein lipase (LPL) 
inhibitor, Apolipoprotein C-III (APOC3)67. APOC-3 is produced in the liver and 
released into circulation attached to very low-density lipoproteins68. In the presence 




seems that fructose is a dual threat to plasma triglyceride clearance; by its ability to 
activate APOC3 and its inability to produce significant insulin release.   
Lastly, protein tyrosine phosphatase-1B (PTP-1B) is a receptor localized on 
the cytoplasmic side of endoplasmic reticulum. It negatively regulates insulin 
signaling in vivo 70,71. Normally, PTP-1B will regulate insulin signaling to match that 
of the body’s demand. The greatest expression of PTP-1B occurs in the absence of 
insulin and in insulin resistant states.  Overexpression of PTP-1B leads to a 
desphosphorylation of insulin receptors and a down regulation of insulin signaling 
molecules72. Chronic fructose feeding causes PTP-1B overexpression in hamsters73 
and mice74.  PTP-1B overexpression shifts hepatic lipid metabolism to favor an 
increase in lipoprotein secretion by increasing apoB100, a required substrate for 
lipoprotein production 74. In that way, fructose promotes increased VLDL synthesis 
and release, and contributes to FIH.  
III. Therapeutics 
Recently, some researchers have focused on finding therapeutic drugs to 
ameliorate fructose-induced hypertriglyceridemia. Several exogenous compounds 
have been tested for their ability to interfere at different steps in the fructose 
metabolism pathway. Some of these findings are discussed below.  
Insulin requires nitric oxide to stimulate glucose uptake.  Fructose raises uric 
acid levels and uric acid inhibits nitric oxide bioavailability.  Allopurinol is a 
zanthene oxidase inhibitor, and in that way can interfere with uric acid synthesis.  
Nakagawa reported that Allopurinol effectively reduced uric acid even in 




hypertriglyceridemia, and hyperuricemia seen in rats fed only HFCS diets without the 
drug. These data provide evidence that uric acid may be important in the connection 
between fructose consumption and metabolic syndrome development.  
Vila has reported that atorvastatin can inhibit triglycerides in plasma, and was 
effective in preventing increased plasma and liver TG accumulation in rats fed a high 
fructose diet76.  Atorvastatin also reduced fatty acid beta oxidation.  It  also increased 
several genes that control fatty acid catabolism, prevented activation of CREBP 
transcriptional activity, blunted liver incorporation of fructokinase and prevented 
histological damage by fructose-induced liver inflammation.  Rasineni77 has shown 
that C. roseus (a subshrub also known as Lochnera rosea)  can prevent fructose-
induced hypertriglyceridemia and lower hepatic fructokinase activity. Another 
therapeutic, Enicostemma littorale Blume extract (EL), successfully lowered TG 
levels by ameliorating glucose tolerance78. EL has HMG-CoA reductase activity that 
allows it to have a hypolipidemic effect as well as beneficial effects on platelet 
aggregation and blood coagulation78. 
 Finally, the antisense oligonucleotide ChREBP ASO (a therapeutic aimed at 
reducing TGs) successfully decreased plasma TG concentrations compared with 
control ASO treatments in rats fed high fat and high fructose diets79. Additionally 
fructose fed rats treated with ChREBP ASO had increased plasma uric acid, alanine 
transaminase and aspartate aminotransferase concentrations due to decreased fructose 
aldose and fructokinase expression79. 
Fibrates are a class of plasma triglyceride lowering drugs that are used 




expression of their associated fatty acid beta-oxidation genes. Additionally, fibrates 
also act to increase the sensitivity of LPL by reducing the expression of the LPL 
inhibitor, APOC381. These three actions by fibrates can lower plasma triglycerides by 
increasing fatty acid beta-oxidation, by interfering with lipolysis, and by increasing 
LPL sensitivity, respectively. Several investigators have reported that fibrates can 
ameliorate fructose-induced hypertriglyceridemia in animal models61,66,82,83.  
Thiazolidinediones (TZD) are a class of anti-diabetic drugs that target peroxisome 
proliferator activated receptor-gamma (PPAR-γ) in adipocytes to improve insulin 
sensitivity . TZD’s can reverse and/or prevent fructose-induced hypertriglyceridemia 
is animal models84-87.   
IV. Summary 
Long-term exposure to dietary fructose (as opposed to glucose) results in 
marked increases in several enzymes that lead to metabolic dysfunction in rats and 
humans. The increases in gene expression such as those noted above, as well as a lack 
of key regulatory steps in initial fructose metabolism favors de novo lipogenesis 
(synthesis of triglycerides) in the liver. As a consequence, there is an overproduction 
of very low-density lipoprotein and triglycerides that are released into circulation, 
leading to hypertriglyceridemia 10,55,56. In contrast, glucose does not increase gene 
expression that facilitates de novo lipogenesis, and thus spares a massive unregulated 
surge of metabolites favoring lipid production. One of the questions for future 
research deals with the safety of the country’s continued use of fructose as a principal 
sweetening agent in our food supply.  As attributed to Paracelsus “The dose makes 




span? Also, there are financial implications to altering a major component of the 
country’s diet that need to be factored in to making such a decision. We look forward 
to several years of scientific debate. 
The review of fructose intake and metabolism presented above has been 
written to facilitate a thorough examination of FIH. Presented below is a summary of 
the work that has been reviewed.  The list is by no means exhaustive, but is offered to 
the reader as an initial guide into an important literature as we continue to grapple 
with developing a thorough assessment of the effects of our use of sugars in our diets. 
These summaries are divided into three types of FIH papers: reviews (like this one), 
papers that focus on some component of the pathway (from fructose intake to 
circulating triglycerides) and papers that focus on assessing the efficacy of exogenous 
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Chapter 2: Fructose intake and circulating triglycerides: an 
examination of the role of APOC 3 
 
Introduction 
Many recent review articles have focused on the increase in fructose 
consumption over the last century and suggest large amounts of fructose in the diet 
can lead to hypertriglyceridemia (HTG) [1-2].  This phenomenon has been replicated 
in both human and animal studies [3-6]. Literature searchers on "fructose AND 
hypertriglyceridemia” reveal that there are several plausible mechanisms that link 
fructose and HTG. In particular, this study will focus exclusively on the examination 
on the role of apolipoprotein CIII (APOC3) in promoting HTG in less than 24 hours.  
  The obesity epidemic that we are experiencing in the US is a national concern 
that affects all Americans.  It does not discriminate among age, race, class, or gender. 
In 1985 the rate of obesity across our country was under 14%; but by 2010 the rate 
exceeded 30% [7].  Furthermore, obesity is quickly becoming a leading cause of 
major health problems and death in the US [8]. The research community, along with 
policy makers and health care officials are grappling to find the causes of this 
relatively sudden increase in American’s girth. Several researchers have targeted 
high-fructose corn syrup as a potential accomplice supporting the obesity epidemic 
[9-12].  They and their supporters have pointed out that fructose has become more 




15g/day. Fructose was consumed mainly through eating fruits and vegetables, which 
have the added benefit of fiber. However, as of 2010, fructose consumption had risen 
to 73g/day and was being consumed in highly processed forms (13).  
The undesirable HTG seen via fructose metabolism is best understood by 
comparing it to the non-lipogenic sugar, glucose. First, fructose metabolism is under 
minimal kinetic control when compared to glucose and can increase metabolites that 
favor triglyceride synthesis (de novo lipogenesis) [14]. This is in part due to the fact 
that all of fructose metabolism occurs in the liver and the liver is the site for 
triglyceride synthesis. Secondly, fructose has been shown to alter genetic expression 
of lipogenic genes that favor increased triglyceride synthesis and reduced plasma 
clearance when compared to glucose [9, 15-17]. Furthermore, fructose does not 
simulate a significant postprandial insulin release, which reduces the livers ability to 
restore homeostasis after a large bolus of fructose when compared to glucose [18]. 
Taken together, it becomes increasingly clearer how fructose can pose a threat to the 
metabolic homeostasis of the liver.  
Apolipoprotein C-III (APOC3) is a lipoprotein that is expressed in the liver of 
humans and rodents. The active APOC3 protein consists of 79 amino acids and has a 
molecular mass of 8.8 kDa. APOC3 is also the most abundant apolipoprotein in 
plasma with an average concentration of about 12 mg/dL. Several studies have shown 
a positive correlation between plasma APOC3 concentration and elevated levels of 
plasma triglycerides & VLDL triglycerides. In addition, several studies have shown 
that a transgenic mouse model that overexpressed or lacked the APOC3 gene resulted 




An attractive hypothesis to the lipogenic nature of fructose is in its ability to 
alter normal hepatic gene expression favoring an increase in lipogenic gene 
expression [19]. APOC3 has become an increasingly popular mechanistic approach 
that links fructose with HTG [17]. One study has replicated this phenomenon in 
chronic fructose feeding (>4 week) [20] but never has it been shown before in an 
acute fructose bolus (<24 hours). Keep in mind that it has been demonstrated already 
that fructose can elicit HTG in 24 hours or less [21]. The question addressed by the 
following experiment is “Is it APOC3 that is responsible for the HTG model in 24 
hours or less?” 
Fructose can indirectly increase hepatic expression of APOC3. APOC-3 is 
produced in the liver and released into circulation attached to very low-density 
lipoproteins [22]. APOC3 is a potent inhibitor of lipoprotein lipase (LPL) [17].  In the 
presence of insulin LPL plays a pivotal role in the clearance of plasma triglycerides 
[23]. However, fructose alone does not stimulate a significant insulin release [18]. 
Thus, it seems that fructose is a dual threat to plasma triglyceride clearance; by its 
ability to activate APOC3 and its inability to produce significant insulin release.   
 The purpose of this study is to test various types of fructose-containing sugars 
(fructose, sucrose and high fructose corn syrup) with the intent of replicating our 
earlier observations that overnight access to fructose can promote HTG as well as to 
examine the role that apolipoprotein C3 (APOC3)  in promoting HTG . Since pure 
fructose is the most lipogenic of all the sugars, we hypothesize that the treatment of 






Materials and Methods 
Animals  
Adult male Sprague-Dawley (CD strain) rats (Charles River Laboratories, 
Wilmington, MA) with a mean weight of approximately 300 grams were used. Upon 
arrival, all animals were individually housed and maintained on a 12h light/dark cycle 
with a room temperature of 22° C ± 1° C. During the 1 wk acclimation period the rats 
were given free access to the control diet and water. Animals were weighed and 24h 
food intake and sugar solution intake (when appropriate) were measured daily at 
0900h throughout the experiment.  
All rats were killed by slow replacement of air in a specialized chamber with 
pure CO2 followed by rapid decapitation and exsanguination. This method has been 
approved for use by the Panel on Euthanasia of the American Veterinary Medical 
Association as well as the UM IACUC. All procedures described herein are in 
compliance with the University of Maryland’s IACUC guidelines.  
 
Animal Diets  
 The control diet is a nutritionally complete low fat diet [Rodent diet 7012] 
prepared by Harlan Teklad (Bethlehem, PA) and provides 3.41 metabolizable kcal/g 




derived from protein, and 0.51 kcal was derived from fat.  All animals were given 
free access to water throughout the experiment. 
Study Design  
After an initial 1 wk acclimation period (during which they had ad lib access 
to food and water), the rats (N=40) were randomly assigned to one of five weight-
matched groups (n=8). Rats assigned to the first group were given ad libitum access 
to control diet (Harlan rodent diet 7012) only, and served as the control group. Rats 
assigned to the second group had ad libitum access to the control diet and free access 
to a 16% weight/volume fructose (Tate & Lyle, Decatur, IL) solution. Rats assigned 
to the third group had ad libitum access to the control diet plus free access to a 16% 
glucose weight/volume (Sigma Aldrich, St Louis MO) solution. Rats assigned to the 
fourth group had ad libitum access to the control diet and free access to 16% high 
fructose corn syrup (HFCS) weight/volume (Tate & Lyle, Decatur, IL), Finally, rats 
assigned to the fifth group had ad libitum access to the control diet and free access to 
a 16% weight/volume sucrose (Domino Foods, Baltimore, MD) solution. All sugar 
solutions were prepared 24h in advance and stored at 4°C. The rats were maintained 
on their respective diets for 24h and then sacrificed. At the time of sacrifice, the lobus 
lateralis sinister of each liver was dissected and flash frozen for storage at -80°C.  
Plasma Measures 
A Rat/Mouse Insulin ELISA Kit was purchased from Milipore, (Cat.# 
EZRMI-13K) and used to quantify insulin in rat plasma. Plasma glucose 




Dimension clinical chemistry system Flex reagent cartridge (Siemens Healthcare 
Diagnostics, Newark, DE) was used with a Dade Behring Dimension Xpand 
automated system to quantify plasma triglyceride levels. A rat APOC3 ELISA kit was 
purchased from NeobioLab (Cat.#RA0523) and used to quantify APOC3 protein 
levels in serum. All plasma measurements were run in duplicate. 
RNA Extraction 
Total RNA was extracted from each liver sample according to RNeasy Mini 
and RNeasy Lipid (QIAGEN) kit directions. The samples were purified with DNA-
free (Ambion) and analyzed spectrophotometrically (Nanodrop) to determine 
concentration and check for quality. cDNA template was created for each sample 




cDNA was made using the SABiosciences RT² First Strand Kit. A genomic 
DNA elimination mixture was first created using 15 µg RNA samples from each 
group (equal quantity from each animal) that was then mixed with 2.0 µl of 5X 
qDNA elimination buffer and RNase-free H20 to a final volume of 10 µl. Contents 
were mixed gently, incubated at 42˚C for 5 minutes and chilled on ice. An RT 
cocktail was then prepared, containing 5X RT Buffer 3, Primer & External Control 
Mix, RT Enzyme Mix 3, and RNase free H20. 10 µl of the RT cocktail was added to 




exactly 15 min and then immediately stopped by heating at 95˚C for 5 min. 91 µl of 
ddH20 was added to each 20 µL of cDNA synthesis reaction and the solution was 
mixed well and stored at -20˚C. 
Measurement of Gene Expression 
Changes in gene expression were measured in each liver sample, n = 40, using 
RT-PCR array. IQ SYBER Green Supermix (BIORAD Cat # 170-8882) was used on 
a C1000 BIO-RAD thermal cycler (CFX96 Real-Time System) to quantify gene 
expression.   
A “housekeeper” or reference gene is used in RT-PCR to enable 
quantification of a target gene. Numerous attempts were made to elucidate a 
“housekeeper” gene that was not influenced by our treatments, including beta-
ACTIN, RPLP1, and GAPDH. Unfortunately, the Ct values of each identified 
“housekeeper” were influenced by the treatments. To correct/normalize the 
“housekeeper” gene in each group a weighting factor was assigned. The weighting 
factor that transformed each sample to match the beta-actin control groups 
“housekeeper” value was selected. In addition, the same weighting factor was applied 
to the target genes Ct values. A sample of how the weighting was conducted is 
provided in table 1. 
Cycle threshold (Ct) values obtained through RT-PCR for all samples are used 
to calculate fold change of gene expression. Fold change was calculated as 2^(-ddCt). 





Custom Primer Design and Optimization  
Primers were designed using Beacon Designer 7 software default parameters 
(PREMIER Biosoft, Palo Alto, CA). These primers include beta-ACTIN, RPLP1, 
GAPDH, and APOC3.  
Primers were evaluated using the CFX96 (BioRad) protocol, using a gradient 
that was centered around predicted optimum annealing temperature (TaOpt). The 
protocol for primer verification PCR is as follows: 95°C, 3 min, and 40 cycles at 
95°C for 10 sec, at a gradient of temperatures for 30 sec with subsequent melt curve 
of 65°- 95°C at increments of 0.5°C for 5 sec. Housekeepers were selected based on 
the least variation in cycles between groups. See 2 for primer sequences. 
Results 
Body Weight 
Twenty-four hour access to any of the four sugar solutions used failed to 
promote significant differences in body weight (p<0.05) (F=0.0571) (df=(4, 38)). 
Refer to body weight data presented in Table .  
There was no significant correlation in the amount of sugar consumed and the 






 Food intake did not differ between groups during the six-day acclimation 
period leading up to the treatment day. The average amount of chow consumed by all 
animals during the acclimation period was 25 grams. However, during the treatment 
period when the rats had access to sugar, the average chow consumption plummeted 
to 18.5 grams. All treatment groups but high fructose corn syrup and fructose ate 
significantly less chow on the treatment day when compared to the control (water) 
group (P<0.05) (F = 4.1631)(df = 4, 37). There were no significant differences 
between any of the treatment groups.   See Figure 1 for values. 
Sugar 
 No differences were observed in the amount of sugar consumed amongst each 
treatment group (P<0.05)(F=1.9691)(df=3, 30). See Table 4 for intake data.  
Total Intake 
 No differences were observed in the amount of total caloric intake amongst 
each group, including control. See table 4 for total intake data (P<0.05) (F=0.2190) 
(df=4, 37). 
Plasma Analyses 
Fructose, HFCS, and sucrose consumption caused significant upregulation in 
circulating triglycerides (P<0.05)(F=13.69)(df=(4,38)) . No differences exist among 
the five groups in plasma insulin (P<0.05) (F=0.12)(df=(4,35)), plasma glucose 
(P<0.05)(F=1.3)(df=(4,35)), and plasma APOC3 (P<0.05)(F=1.35)(df=(4,38)). Refer 





 It has long been recognized that the selection of a housekeeper gene should be 
determined by that gene’s resistance to treatment effects.  We examined several 
standard housekeepers and found that all were significantly affected by sugar solution 
consumption (Duncan’s new multiple range test).The housekeepers that were tested 
include beta-actin (P<0.05)(F=18.5)(df=(4,37)), Ribosomal protein large protein1 
(RPLP1) (P<0.05)(F=20.9)(df=(4,37)), and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (P<0.05)(F=18.9)(df=(4,37)). Refer to housekeeper 
selection data presented in figure 2.  
 It was discovered that our treatment groups could influence all of the 
housekeepers Ct values by a particular replicable pattern.  The Ct values of both the 
Fructose and the control groups were always significantly higher than the other 
groups but did not differ from one another. This observation was the result of all 
available housekeepers tested. Refer to housekeeper selection data presented in Table 
6.  
APOC3 Gene Expression 
 After normalizing the housekeepers Ct values and adjusting the weighting 
factor for each group, there were some differences in gene expression among the 
treatment groups. The water group was our control and reference group for which 
APOC3 gene expression fold change was measured. The sucrose, & glucose groups 
had similar significantly positive fold changes at 2.68, and 2.59, respectively when 




positive fold change of 2.40 but was not considered significant by the means 
ANOVA. Fructose elicited a negative fold change at 0.86 but was not considered 
significant but the means ANOVA. Refer to APOC3 gene expression presented in 
figure 3. 
Discussion 
There is an alarming obesity epidemic in this country. The obesity problem is 
particularly worrying not only in terms of human health and quality of life but also in 
terms of dollars currently spent and will be spent on healthcare in the treatment of 
obesity related comorbidities. Obesity has become the nation’s most preventable 
health problem [24-25]. 
Despite it’s prevalence, there is no known cure for this disease or consensus 
about how it develops. One hypothesis for the cause of obesity is that dietary intake 
patterns of Americans have significantly shifted over the past fifty years by including 
unprecedented amounts of refined sugar [26].    
The purpose of this experiment was to examine this hypothesis by evaluating 
how sugars affect triglyceride metabolism in the liver. Animals were given 24-hour 
access to either a dilute glucose, sucrose, HFCS, or fructose sugar solution. Intake of 
both chow and sugar was measured. Hepatocyte tissue was collected and changes in 
APOC3 gene expression were measured using a RT-PCR assay for the different 





 Previous studies have shown that initial presentation of a sugar solution will 
result in rats consuming excess calories from sugar. Over time however this result 
washes out and total caloric intake returns to a level that resembles control [27-28].  
These findings did not support previous studies that showed an increase in kcal upon 
initial presentation of sugar access. Our findings suggest that all animals were able to 
selectively regulate their overall total intake regardless off the type of sugar 
presented. All sugar-fed animals consumed the same amount of total calories and 
there were no differences in percent kcal from sugar for groups consuming fructose-
containing sugars (sucrose, HFCS, fructose). 
The rats in this experiment did not increase intake of glucose-fructose 
disaccharides (sucrose and HFCS) in such a way as to match the amount of fructose 
consumed in the fructose group. In other words rats did not have a threshold for 
fructose consumption and compensate by consuming 50% more sucrose or 45% more 
HFCS to match the total consumption of fructose in the fructose fed group. We 
applied the same model as Collier and Bolles did in their 1968 sugar dilution studies. 
Looking at intake of various sugar dilutions in rats, Collier and Bolles found that 
regardless of the type of sugar presented, rats will increase their intake of a dilute 
sugar so as to take in a certain threshold amount of total grams of sugar [29]. In the 
current study, this model was applied to dilutions of fructose intake. For example, 
sucrose fed animals had a solution that was 50% less fructose than the fructose 
animals. Replicating Collier and Bolles’ findings, there was not set level for fructose 




the same amount of total kcal from sugar. These findings also show that fructose 
having a sweeter taste than glucose did not impact intake. 
Plasma 
Fructose, high-fructose corn syrup, and sucrose caused a significant and 
robust increase in triglycerides with only 24 hours of access. Others have 
demonstrated that fructose alone could elicit HTG in 24 hours but never has sucrose 
and high-fructose corn syrup resulted in HTG in only 24 hrs. The importance of this 
finding is that hypertriglyceridemia occurred with only 24-hour access to fructose and 
in addition with other fructose containing sugars.  
No differences in plasma insulin, glucose, and APOC3 were observed, as all 
blood samples were collected under ad libitum feeding conditions.  
Gene Expression 
 The reoccurring pattern of group differences for each housekeeper inhibited 
our ability to quantify gene expression using traditional methods. Traditionally, a 
housekeeper is defined by not being affected by the treatment itself and is used as a 
reference in 2^(-ddCt) equation. Some collaboration with experts in using RT-PCR 
was required before concluding that a weighting factor was a viable option. The 
control group in our experiment became the reference Ct value that was needed to 
correct for all other grouped beta-actin & APOC3 values and eventually applied to 




 An obvious limitation to the APOC3 gene expression results includes the 
manipulation of data as seen in the weighting factor that was applied. However, many 
attempts were made to elucidate a housekeeper gene that would allow the use of the 
more traditional method in gene expression studies. Each housekeeper was tested 
twice with duplicate sample data. In addition, the selection of housekeepers to be 
tested came from literature searchers that suggested they are widely utilized in the 
scientific community.  
 However limited the results may be, they are much different than expected. 
The available literature suggests that APOC3 is a possible link to eliciting 
hypertriglyceridemia via increased mRNA gene expression in liver that leads to 
increased protein expression in circulation. The literature also suggests chronic 
fructose consumption leads to an increase in APOC3 mRNA and Protein levels. 
Therefore, the current studies hypothesis was that treatment groups with the highest 
fructose concentration would have highest levels of APOC3, both message and 
protein. Interestingly, the results from this study tell quite a different story. The 
groups containing glucose (glucose, sucrose, and high-fructose corn syrup) elicited 
the highest APOC3 mRNA concentration in the liver compared to the control. The 
pure fructose treatment group, which was thought to increase APOC3 message the 
most, deviated from the hypothesis by slightly decreasing the message compared to 





 This study contributed a few novel items to the literature on fructose-induced 
HTG. First, this study confirmed that fructose-induced HTG could be elicited in 24 
hrs. or less in many of the readily available fructose containing sugars (fructose, 
sucrose, and high-fructose corn syrup). Not to mention that in the experimental design 
the animals had free access to sugars for the first time and could control their own 
intake, which makes it physiologically relevant. Secondly, this study tested the 
validity of APOC3 and its role in the fructose-induced HTG mechanism in 24 hrs or 
less. Contrary to other studies that suggest APOC3 is responsible for HTG, here we 
conclude that there is an alternative mechanism to elicit HTG in 24 hrs or less that has 
not yet been identified. To be certain a more comprehensive study needs to be 
designed that could measure the ratios of other lipoproteins involved in newly 
synthesized VLDL and test their relative proportionalities to APOC3. This could 













Table 1. Example of weighting factor used for the “housekeeper” beta-actin 
Rat # Ct value Group Water 
avg. Ct 
Water 
avg. Ct / 
Ct value  
  
1A 22.57 W 21.87 *Represe











7A 22.23 W 21.87  17.04  
10A 22.13 W 21.87  16.16  
15A 20.54 W 21.87  15.61  
9A 19.14 S 21.87 *1.14 16.71 19.09 
18A 18.92 S 21.87 *1.16 13.69 15.83 
19A 19.30 S 21.87 *1.13 14.48 16.40 
3A 21.75 HF 21.87 *1.01 16.19 16.27 
11A 21.46 HF 21.87 *1.02 15.04 15.32 
16A 19.97 HF 21.87 *1.09 14.95 16.36 
20A 19.00 HF 21.87 *1.15 13.99 16.10 
 
Rat # is used for identification purposes. Ct value is obtained via RT-PCR and 
represents relative threshold amount of amplified beta-actin mRNA. The Group 
identifiers are W (water, control), S (sucrose, treatment), and HF (high fructose corn 
syrup, treatment). The water average Ct value represents the “housekeeper” value for 
the control group. Water avg. Ct / Ct value is represented as a percentage, which is 
used as the weighting factor for subsequent use. APOC3 Ct is multiplied by the 
weighting factor to produce the corrected APOC3 Ct value as seen in the last column. 
Please find a more simplified equation here; Y (Corrected APOC3)= [ X (avg ct value 











































Primers were designed using Beacon Designer 7 unless otherwise noted in Methods 
section.  





  Control Glucose Sucrose HFCS Fructose 
Average BW (g) 293.8a 292.2a 295.1a 292.7a 289.8a 
SEM +8.8 +8.4 +8.0 +7.4 +8.7 
 
Average body weight in grams. Rats were weighed prior to sacrifice. Averages that 
share a common superscript are not different from one another (F=0.0571; df=(4,38). 
Standard error of the mean (SEM) is presented below the averages for each group. No 


























Table 4. Average sugar, chow and total intake in kcal following 24-hour sugar access. 
Group Sugar-Kcal SEM %Kcal 









     
Control 
na na 0 93.1a +10.8 100 93.1a +10.8 
Sucrose 52.7a +3.9 51.5 49.6b +7.4 48.5 102.3a +7.8 
HFCS 44.6a +3.4 43.8 57.2b +8.7 56.2 101.8a +7.0 
Fructose 38.8a +5.7 40.2 57.7b +12.1 59.8 96.5a +15.2 
Glucose 46.2a +2.2 50 46.2b +5.2 50 92.4a +4.8 
 
Mean intake of kilocalories derived from sugar and chow on treatment day. There are 
no significant differences in the amount of kcals derived from the sugar treated 
groups (F=1.9691)(df=3, 30) or total kcals from sugar + chow (F=0.2190) (df=4, 37). 
Standard error of the mean (SEM) is presented beside the averages for each group. 




















Table 5. Average Triglycerides, Insulin, Glucose, and APOC3 in Plasma following 
24-hr sugar access. 
Group Insulin 
ng/mL 





Water 4.2a +0.6 73.4c +20.7 150.0a +2.0 321.9a +53.7 
Sucrose 4.5a +0.7 257.4ab +30.3 149.9a +2.1 333.8a +71.1 
HFCS 4.2a +0.9 286.2a +31.6 148.8a +3.6 243.9a +64.4 
Fructose 4.5a +0.9 311.6a +41.6 155.7a +2.9 412.7a +87.4 
Glucose 4.4a +1.1 132.1bc +20.6 147.2a +3.4 208.4a +57.0 
  
Group means are presented here for plasma insulin, triglycerides, glucose, and 
APOC3. Superscripts with different letters indicate a significant difference at the 
P<0.05 level. The treatments were only effective in eliciting a significant difference 
in the triglyceride assay as indicated by the subscripts (P<0.05)(F=13.69)(df=(4,38)). 
The statistics for insulin, glucose and APOC3 are (F=0.12)(df=(4,35)), 
(F=1.3)(df=(4,35)), and (F=1.35)(df=(4,38)), respectively. Standard error of the mean 






















Table 6.  Housekeeper Ct Values 
Group Beta-
Actin 
SEM RPLP-1 SEM GAPDH SEM 
Water 21.9a +0.3 19.7a +0.2 18.6a +0.1 
Fructose 22.2a +0.2 19.5a +0.3 18.8a +0.3 
Glucose 20.2b +0.2 18.3b +0.2 17.1b +0.2 
HFCS 20.7b +0.4 18.2b +0.2 17.2b +0.3 
Sucrose 19.4c +0.1 17.6c +0.2 16.2c +0.2 
 
Group means are presented here for three different housekeepers. The housekeepers 
that were tested include beta-actin (P<0.05)(F=18.5)(df=(4,37)), Ribosomal protein 
large protein 1 (RPLP1) (P<0.05)(F=20.9)(df=(4,37)), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (P<0.05)(F=18.9)(df=(4,37)). Superscripts with 
different letters indicate a significant difference at the P<0.05 level. Each 
housekeeper produced the same pattern for group differences. Standard error of the 





















Figure 1. Twenty-four hr. Chow Intake on Treatment Day 
 
The sucrose and glucose groups ate significantly less chow on the treatment day when 
compared to the control (water), (F = 4.1631)(df = 4, 37. There are no significant 
differences between any of the sugar treated groups. Means sharing the same letter 
















Figure 2. Example of Reoccurring Housekeeper Data 
 
Group mean Ct values for RPLP1 are presented here. Groups sharing the same letter 


















Figure 3. APOC3 mRNA Gene Expression 
 
  
APOC3 mRNA gene expression is presented here with regards to fold changes using 
the 2^(-ddCt) equation. Only the glucose containing sugars sucrose, HFCS, and 
glucose were able to positively increase the mRNA expression of APOC3 in a 
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